Immunogenicity and Safety of Three Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Adults Aged 18 to 45 Years in the US.

Trial Profile

Immunogenicity and Safety of Three Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Adults Aged 18 to 45 Years in the US.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2014

At a glance

  • Drugs CYD TDV (Primary)
  • Indications Dengue
  • Focus Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 18 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 May 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 18 May 2010 Actual patient number (260) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top